

INTRODUCING

THE NUBEQA® 30-DAY FREE SAMPLE PROGRAM

Start your appropriate patients
on treatment right in your office



The NUBEQA Free Sample Program may allow you to start your patients on NUBEQA quickly

Please read the following pages for important information for prescribers, patients, and pharmacies.



NUBEQA®
(darolutamide) 300 mg tablets

INDICATIONS

NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with:

- non-metastatic castration resistant prostate cancer (nmCRPC)
- metastatic castration-sensitive prostate cancer (mCSPC)
- metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel

IMPORTANT SAFETY INFORMATION

Warnings & Precautions

Ischemic Heart Disease – Ischemic heart disease, including fatal cases, occurred in patients receiving NUBEQA.

In a pooled analysis of ARAMIS and ARANOTE, ischemic heart disease occurred in 3.4% of patients receiving NUBEQA and 2.2% receiving placebo, including Grade 3-4 events in 1.4% and 0.3%, respectively. Ischemic events led to death in 0.4% of patients receiving NUBEQA and 0.4% receiving placebo.

Please see additional Important Safety Information throughout and the full [Prescribing Information](#).

START TREATMENT WITH THE NUBEQA® 30-DAY FREE SAMPLE PROGRAM

The NUBEQA Free Sample Program will give you the opportunity to

- Start your patients on NUBEQA right in your office
- Provide your patients with a 30-day supply of NUBEQA at no cost

Ordering a sample is simple

- Contact your sales representative, who will process your sample request
- Your order will be shipped within 24 to 48 hours



For illustrative purposes only.

IMPORTANT SAFETY INFORMATION (continued)

Warnings & Precautions (continued)

Ischemic Heart Disease (cont'd) – In ARASENS, ischemic heart disease occurred in 3.2% of patients receiving NUBEQA with docetaxel and 2% receiving placebo with docetaxel, including Grade 3-4 events in 1.3% and 1.1%, respectively. Ischemic events led to death in 0.3% of patients receiving NUBEQA with docetaxel and 0% receiving placebo with docetaxel.

Monitor for signs and symptoms of ischemic heart disease. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue NUBEQA for Grade 3-4 ischemic heart disease.

Seizure – Seizure occurred in patients receiving NUBEQA.

In a pooled analysis of ARAMIS and ARANOTE, Grade 1-3 seizure occurred in 0.2% of patients receiving NUBEQA. Seizure occurred from 261 to 665 days after initiation of NUBEQA.

In ARASENS, seizure occurred in 0.8% of patients receiving NUBEQA with docetaxel, including two Grade 3 events. Seizure occurred from 38 to 1754 days after initiation of NUBEQA.

It is unknown whether anti-epileptic medications will prevent seizures with NUBEQA. Advise patients of the risk of developing a seizure while receiving NUBEQA and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others. Consider discontinuation of NUBEQA in patients who develop a seizure during treatment.

How to dispense the sample

- Identify patients who are appropriate for NUBEQA
- Give the appropriate patients both the sample and the patient brochure
- Patient starter kits are also available from your sales representative

After dispensing the sample, initiate the prescription process for your patients

- Visit NUBEQAhcp.com to download the patient request form
- Use covermymeds.com
- Access Services by Bayer™ can help you with reimbursement, access, benefit verification, prior authorization assistance, and appeal support. Please call 1-800-288-8374 Monday-Friday, 8:00 AM - 8:00 PM (ET)



IMPORTANT SAFETY INFORMATION (continued)

Warnings & Precautions (continued)

Embryo-Fetal Toxicity – The safety and efficacy of NUBEQA have not been established in females. NUBEQA can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception during treatment with NUBEQA and for 1 week after the last dose.

Adverse Reactions

In ARAMIS, serious adverse reactions occurred in 25% of patients receiving NUBEQA and in 20% of patients receiving placebo. Serious adverse reactions in $\geq 1\%$ of patients who received NUBEQA included urinary retention, pneumonia, and hematuria. Fatal adverse reactions occurred in 3.9% of patients receiving NUBEQA and 3.2% of patients receiving placebo. Fatal adverse reactions that occurred in ≥ 2 patients who received NUBEQA included death (0.4%), cardiac failure (0.3%), cardiac arrest (0.2%), general physical health deterioration (0.2%), and pulmonary embolism (0.2%). The most common ($>2\%$ with a $\geq 2\%$ increase compared to placebo) adverse reactions, including laboratory test abnormalities, were increased AST (23%), decreased neutrophil count (20%), fatigue (16%), increased bilirubin (16%), pain in extremity (6%), and rash (4%). Clinically relevant adverse reactions occurring in 2% or more of patients treated with NUBEQA included ischemic heart disease (4%) and heart failure (2.1%).

Please see additional Important Safety Information throughout and the full [Prescribing Information](#).


NUBEQA[®]
(darolutamide) 300 mg tablets

NUBEQA® Free Sample Program Requirements

- The NUBEQA Free Sample Program provides NUBEQA at no cost for up to 30 days to eligible patients
- The NUBEQA Free Sample Program is only valid in the United States and Puerto Rico and is void where restricted or prohibited by law
- Qualifying prescriptions for the NUBEQA Free Sample Program must be for an on-label use of NUBEQA
- Participation in the NUBEQA Free Sample Program is not contingent on any past, present, or future prescriptions for, or purchase of, NUBEQA or any other Bayer product. No purchase or refills are required
- If applicable, patient is responsible for any taxes or costs associated with shipment of product
- The program is available to all patients, irrespective of drug coverage
- Bayer reserves the right to rescind, revoke, or amend the NUBEQA Free Sample Program at any time for any reason without prior notice
- By enrolling in the NUBEQA Free Sample Program, the prescribing physician agrees to these requirements
- Bayer cannot ensure continuity of care after the initial sample is dispensed for Medicare Part D patients who may experience co-pay and/or reimbursement challenge with their federally funded insurance program

IMPORTANT SAFETY INFORMATION (continued)

Adverse Reactions (continued)

In ARANOTE, serious adverse reactions occurred in 24% of patients receiving NUBEQA. Serious adverse reactions in $\geq 1\%$ of patients who received NUBEQA included pneumonia (2%), urinary tract infection (1.8%), musculoskeletal pain (1.6%), hemorrhage (1.6%), arrhythmias (1.3%), and spinal cord compression (1.1%). Fatal adverse reactions occurred in 4.7% of patients receiving NUBEQA and those that occurred in ≥ 2 patients included sepsis (1.1%), craniocerebral injury (0.4%), and myocardial infarction (0.4%). The most common ($\geq 10\%$ with a $\geq 2\%$ increase compared to placebo) adverse reaction is urinary tract infection (12%). The most common laboratory test abnormalities ($\geq 15\%$ with a $\geq 5\%$ increase over placebo) are increased AST (32%), increased ALT (28%), increased bilirubin (17%), and decreased neutrophil count (16%). Clinically relevant adverse reactions in $< 10\%$ of patients who received NUBEQA included arrhythmia (8.8%), pneumonia (3.6%), and myocardial infarction (0.7%).

In ARASENS, serious adverse reactions occurred in 45% of patients receiving NUBEQA with docetaxel. Serious adverse reactions in $\geq 2\%$ of patients who received NUBEQA with docetaxel included febrile neutropenia (6%), neutrophil count decreased (2.8%), musculoskeletal pain (2.6%) and pneumonia (2.6%). Fatal adverse reactions occurred in 4% of patients receiving NUBEQA with docetaxel. Fatal adverse reactions in ≥ 2 patients who received NUBEQA included COVID-19/COVID-19 pneumonia (0.8%), myocardial infarction (0.3%), and sudden death (0.3%).

No-cost Supply of NUBEQA Requirements

- The no-cost supply of NUBEQA is not insurance
- The no-cost supply of NUBEQA may not be billed in whole or part to any patient or insurer
- The no-cost supply of NUBEQA may not be sold, purchased, or traded
- By accepting the no-cost product, the patient agrees to these requirements

IMPORTANT SAFETY INFORMATION (continued)

Adverse Reactions (continued)

The most common ($\geq 10\%$ with a $\geq 2\%$ increase over placebo with docetaxel) adverse reactions are constipation (23%), rash (20%), decreased appetite (19%), hemorrhage (18%), increased weight (18%), and hypertension (14%). The most common laboratory test abnormalities ($\geq 30\%$) are anemia (72%), hyperglycemia (57%), decreased lymphocyte count (52%), decreased neutrophil count (49%), increased AST (40%), increased ALT (37%), and hypocalcemia (31%). Clinically relevant adverse reactions in $< 10\%$ of patients who received NUBEQA with docetaxel included fractures (8%), ischemic heart disease (3.2%), seizures (0.6%), and drug-induced liver injury (0.3%).

Drug Interactions

Effect of Other Drugs on NUBEQA – Concomitant use of NUBEQA with a combined P-gp and strong or moderate CYP3A4 inducer decreases darolutamide exposure which may decrease NUBEQA activity. Avoid concomitant use of NUBEQA with combined P-gp and strong or moderate CYP3A4 inducers.

Concomitant use of NUBEQA with a combined P-gp and strong CYP3A4 inhibitor increases darolutamide exposure which may increase the risk of NUBEQA adverse reactions. Monitor patients more frequently for NUBEQA adverse reactions and modify NUBEQA dosage as needed.

Effects of NUBEQA on Other Drugs – NUBEQA is an inhibitor of BCRP transporter. Concomitant use of NUBEQA increases the AUC and C_{max} of BCRP substrates, which may increase the risk of BCRP substrate-related toxicities. Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions, and consider dose reduction of the BCRP substrate drug.

NUBEQA is an inhibitor of OATP1B1 and OATP1B3 transporters. Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates. Monitor patients more frequently for adverse reactions of these drugs and consider dose reduction while patients are taking NUBEQA.

Review the Prescribing Information of drugs that are BCRP, OATP1B1, and OATP1B3 substrates when used concomitantly with NUBEQA.

Please see additional Important Safety Information throughout and the full [Prescribing Information](#).



CHOOSE NUBEQA® FOR YOUR PATIENTS WITH mCSPC AND nmCRPC



Please see additional Important Safety Information throughout
and the full [Prescribing Information](#).



© 2025 Bayer. All rights reserved. Bayer, the Bayer Cross, and NUBEQA are registered trademarks of Bayer,
and Access Services by Bayer is a trademark of Bayer. PP-NUB-US-4252-1 06/25


NUBEQA®
(darolutamide) 300 mg
tablets